- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
University of Cincinnati Cancer Center | Strategic Alliance Partners
.jpg?fit=crop&auto=format)
The University of Cincinnati Cancer Center provides the overarching support for all cancer education and research efforts within the UC College of Medicine, UC Health, and Cincinnati Children’s to enhance collaboration among researchers and clinicians. Our vision is to build a nationally recognized center that excels in research, training, community impact, and that makes the most advanced care readily available to the people in the communities we serve.
Latest from University of Cincinnati Cancer Center
Dr. Herzog on the Use of HIPEC in Ovarian Cancer
October 09, 2018
Video
Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Dr. Herzog on Impact of Recent Clinical Trials in Ovarian Cancer
September 04, 2018
Video
Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.
Herzog Highlights History and Future of Frontline Ovarian Cancer Care
August 30, 2018
Article
Thomas Herzog, MD, traces the therapeutic evolution of frontline treatment for patients with ovarian cancer.
Dr. Herzog on Novel Therapies in Ovarian Cancer
August 27, 2018
Video
Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.
Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian Cancer
August 21, 2018
Video
Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the optimal use of bevacizumab (Avastin) in patients with ovarian cancer.
Maintenance Niraparib Improves PFS in Ovarian Cancer
June 29, 2016
Article
Maintenance therapy with niraparib improved progression-free survival compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA mutation or homologous recombination deficiency.
Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC
September 30, 2015
Video
John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.
Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell Lymphoma
September 22, 2015
Video
Tahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).
Novel Immunotherapy Shows Promise in Metastatic Cervical Cancer
September 17, 2015
Article
Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.
Dr. Hashemi Sadraei Discusses Biomarkers in HPV-Induced Tumors
July 30, 2015
Video
Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.
Gender Disparities and Other DLBCL Developments
July 28, 2015
Article
Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.